To identify therapeutically exploitable vulnerability linked to deleterious RB1 mutation we assessed the sensitivity of histotype-matched cancer cell line pairs differing in RB1 mutation status to clinical candidate agents that target DNA metabolic processes. The gene discussed is RB1; the disease is cancer.